Posts Tagged: drug pricing


Will Bayh-Dole Survive Its 40th Birthday?

Next year marks the 40th anniversary of the passage of the Bayh-Dole Act. With election day looming, 2020 is likely to be the most politically contentious year of …
By Joseph Allen
2 months ago 1

As Lighthizer Negotiates on USMCA, Former HHS Secretary Warns Against Buying Into ‘Myths’

On September 13, U.S. Trade Representative Robert Lighthizer reportedly expressed a willingness to negotiate on several points of contention regarding the U.S.-Mexico-Canada Agreement (USMCA), including …
By IPWatchdog
3 months ago 0

Don’t Ignore the Flashing Caution Lights in the Drug Pricing Debate

Trying to rationally address hot button issues in an election year is always a dangerous proposition. That's particularly true as we approach what promises to be one …
By Joseph Allen
3 months ago 1

Other Barks & Bites for Friday, July 12: Final Rule on Drug Prices in TV Ads Blocked, Huawei Pronounced Top Chinese Patent Earner, and Brazil Joins Madrid Agreement

This week in Other Barks & Bites: The Trump Administration’s Final Rule that would have required list prices of drugs to be displayed in television ads is …
By IPWatchdog
5 months ago 0

Amidst Push for a Summer Vote on USMCA, Report Argues RDP Requirement Would Not Raise Drug Prices

In the face of pressure to pull provisions in the United States-Mexico-Canada Agreement (USMCA) that would grant 10 years of regulatory data protection (RDP) for biologics inventions, a …
By Eileen McDermott
5 months ago 0

This Week on Capitol Hill: Drone Security Developments, Clean Energy Innovations, and Think Tanks Look at Patent Reform and Drug Pricing

This week, the U.S. Senate will hold hearings on enhancing drone innovation and addressing cybersecurity concerns; reducing prescription drug prices; and developments in geothermal energy technologies. …
By IPWatchdog
6 months ago 1

House Drug Pricing Hearing Goes Off Script

Most Congressional hearings are morality plays designed to reach a predetermined outcome. It wasn't hard to predict how the second hearing on drug pricing by the House …
By Joseph Allen
7 months ago 5

Jamie Love Responds to Criticism of Knowledge Ecology International Letter

On May 12, Frederick Reinhart published an article titled “Knowledge Ecology International Letter Misleads on March-In Rights.” Reinhart is a past president of the Association of University Technology …
By James Love
7 months ago 6

The Price of Price Controls: Innovation Likely to Suffer in Drug Pricing Debate

Is Congress really going to do anything useful with respect to lowering drug prices? When the question is presented that way the answer almost seems painfully obvious. …
By Gene Quinn
7 months ago 33

Accelerating Generic Entry: A Proven Solution to the Problem of Prescription Drug Pricing

High prescription drug prices and their impact on costs borne by the government in Medicaid, Medicare Part D and other federal programs, is a front burner topic …
By Bert Rein
7 months ago 15

This Week on Capitol Hill: Clean Energy Innovation, More Debate on Prescription Drug Pricing and Technological Censorship of Free Speech

The Senate has a busy schedule related to tech and innovation topics for the week of April 8, including hearings on prescription drug pricing, broadband Internet coverage maps …
By IPWatchdog
8 months ago 0

IP and Innovation on Capitol Hill: Week of April 1: Medicare Drug Pricing, Lost Einsteins and Data Privacy

This week on Capitol Hill will include a series of hearings related to tech and innovation topics on Tuesday at the House of Representatives, where debate will …
By IPWatchdog
8 months ago 0

IP and Innovation on Capitol Hill: Week of March 11

This week on Capitol Hill, both houses of Congress are abuzz with a full schedule of hearings related to science, technology and innovation topics. In the House …
By IPWatchdog
9 months ago 1

IP and Innovation on Capitol Hill: Week of March 4

This week on Capitol Hill and in the Washington D.C. area, the Supreme Court grants cert in Iancu v. NantKwest; the U.S. House of Representatives …
By IPWatchdog
9 months ago 0

Examining the Truvada #BreakThePatent Debate: Gilead Responds

In July 2012, the U.S. Food and Drug Administration (FDA) first approved Truvada, an acquired immunodeficiency syndrome (AIDS) treatment manufactured by Gilead Sciences as a daily pre-exposure …
By Steve Brachmann
9 months ago 3